Ivan Diaz-Padilla, MD, PhD

Ivan Diaz-Padilla is board-certified in Medical Oncology by the Spanish Ministry of Health.

After his foundational medical oncology residency training in Madrid, and a preceptorship in Early Drug Development at the Royal Marsden Hospital in London, UK, he subsequently completed a two-year clinical research fellowship in Gynecologic Oncology and Drug Development at the Princess Margaret Cancer Center in Toronto, Canada. Ivan obtained his PhD from the University of Seville, Spain, for his clinical and translational research on the role of notch inhibition in ovarian cancer.

Dr. Diaz-Padilla accumulated more than ten years of clinical practice experience before moving into the pharmaceutical industry. In April 2013 he joined the department of Oncology Global Development at Novartis, where he was a member of the clinical development team that ultimately led alpelisib to be the first-in-class PI3K inhibitor approved in breast cancer. Subsequently, Ivan led the clinical development of the CDK4/6 inhibitor ribociclib in premenopausal women with metastatic hormone-receptor sensitive breast cancer, achieving its registration. From January 2019 until March 2021, Ivan served as the Global Clinical Development Lead for the DNA-damage repair (DDR) portfolio at Merck KGaA/EMD Serono, where he was accountable for the early clinical strategy of three DDR programs (DNA-PKi, ATRi, and ATMi).

In April 2021 Dr. Diaz-Padilla joined GSK. In his current role as Global Clinical Head Immuno-Oncology, Dr. Diaz-Padilla oversees a team of medical directors and clinical scientists responsible for the implementation of the clinical development strategy of all the assets across the GSK Immuno-Oncology portfolio, from proof-of-concept to registration.

Based in Zug, Switzerland, Ivan is married, has two daughters and enjoys practicing sports, like skiing, swimming, cycling, and running.